Inhaled antibiotics market

Q: Which is the leading Product type segment in the market?

Aerosol is the leading segment in the market. Read more

Inhaled Antibiotics Market, by Product Type (Aerosol, Dry Powder Formulation, and Spray), by Application (Pneumonia, Asthma, Bronchitis, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

Request Free Sample

Jul 2023
CMI3980
180 Pages
Excel & Pdf
Pharmaceutical

Summary

The global Inhaled antibiotics market is estimated to be valued at US$ 1,403.3 Million in 2023 and is expected to exhibit a CAGR of 6.7% during the forecast period (2023-2030).

Analysts’ Views on Global Inhaled Antibiotics Market:

Global Inhaled Antibiotics Market has gained momentum in recent times because of the increasing incidence of chronic respiratory disorders such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis. Furthermore, an increase in research and development and company initiatives are the factors for the growth of the inhaled antibiotics which shows significant opportunities for global Inhaled Antibiotics Market growth over the forecast period. Investments in the development of inhaled antibiotics are a key trend gaining popularity in inhaled antibiotics market. Major pharmaceutical companies are investing in the development of inhaled antibiotics to sustain its position in the market.

Figure 1. Global Inhaled Antibiotics Market Share (%), By Product Type, 2023

Global Inhaled Antibiotics Market– Driver

Rising incidence of respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis

Rising incidence of respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis is expected to drive the market growth over the forecast period. For instance, according to the World Health Organization, report in May 2020, asthma is the most common chronic disease among children worldwide and around 339 million people were living with asthma in 2016. Similarly, according to the same source, over 80% of asthma-related deaths occur in low-and lower-middle income countries.

Growing geriatric population

Growing geriatric population can also drive the inhaled antibiotics market growth. For instance, according to an article published in World Health Orgnisation, in November 2022, reported 1 in 6 people in the world will be aged 60 years or over. At this time the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. By 2050, the world’s population of people aged 60 years and older will double (2.1 billion). Non- cystic fibrosis bronchiectasis is the most common in elderly and frailer patients with estimated cases of 50% in patients over 65 years of age and 19.1% in patients over 75 years old.

Figure 2. Global Inhaled Antibiotics Market Share (%), By Region, 2023

Global Inhaled Antibiotics Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global inhaled antibiotics market over the forecast period. North America is estimated to hold 36.3% of the market share North America holds a significant market share in the Inhaled antibiotics market worldwide, mainly due to the key market players are focusing on inorganic statergies such as merger and increased manufacturing of inhaled antibiotics. For instance, EnBiotix, Inc., a rare disease company focused on chronic respiratory disorders in U.S., announced the closing of an $11M pre-merger, convertible note round of financing comprised of Vectura Group plc, the Cystic Fibrosis Foundation and Sanford Biosciences LLC is developing medicines for unmet patient needs and responding to the demand for increased access to biologic treatments. Thus, North America is also projected to spur the global inhaled antibiotics market growth over the forecast period.

Global Inhaled Antibiotics Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a positive impact on the global inhaled antibiotics market. For instance, an article published in the National Library of Medicine, in August 2020, reported the prevalence of Staphylococcus aureus infection in respiratory cultures and diagnostic performance of nasal polymerase chain reaction (PCR) in patients hospitalized with coronavirus disease 2019 (COVID-19) pneumonia.

Inhaled Antibiotics Market Report Coverage

Report Coverage	Details
Base Year:	2022	Market Size in 2023:	US$ 1,403.3 Mn
Historical Data for:	2017 to 2021	Forecast Period:	2023 to 2030
Forecast Period 2023 to 2030 CAGR:	6.7%	2030 Value Projection:	US$ 2,213.2 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Product Type: Aerosol, Dry Powder Formulation, Spray By Application: Pneumonia, Asthma, Bronchitis, Others By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:	Gilead Sciences, Aradigm, Lupin Ltd., Polyphor, Insmed Incorporated, Pharmaero, Savara Pharmaceuticals, Joincare Pharmaceutical Group, Teva Pharamceuticals, Altan Pharmaceuticals, Raptor Pharmaceutical Corp., Cipla Limited, Maya Biotech Pvt. Ltd., Medisol Lifescience Pvt. Ltd., Nivon Specialties, Sentiss Pharma Pvt. Ltd., Ultratech India Limited, Midas Care Pharmaceuticals Pvt Ltd., Precept Pharma Ltd., Luckys Pharma, and Pharmaxis Ltd.
Growth Drivers:	Rising incidence of respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis Growing geriatric population
Restraints & Challenges:	Side effects associated with drug inhalation and unattainability of single effective inhaler device

Global Inhaled Antibiotics Market Segmentation:

The global Inhaled Antibiotics market report is segmented into By Product Type, By Application, By Distribution Channel, and By Region.

By Product Type, the global inhaled antibiotics market is segmented into aerosol, dry powder formulation, and spray. Out of which, the aerosol segment is expected to dominate the inhaled antibiotics market during the forecast period and this is due to the high prevelance of infectious disease.

By Application, the global inhaled antibiotics market is segmented into pneumonia, asthma, bronchitis, and others. Out of which, the pneumonia segment is expected to dominate the global inhaled antibiotics market during the forecast period and this is due to the increasing several infectious agents, including viruses, bacteria and fungi.

By Distribution Channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Out of which, the hospital pharmacies segment is expected to dominate the market over the forecast period and this is attributed to the providing drug information and adequate statistics on medication consumptions.

Among all the segmentations, the product type has the potential due to the increasing respiratory tract infection this is expected to drive the growth of the segment over the forecast period. For instance, in April 2022, according to the World Health Organization (WHO), reported respiratory infections account for 6% of the total global disease burden. Around 6.6 million, under-five aged children years of age die each year worldwide; 95 percent of them belong to low-income countries and one third of the total deaths is due to acute respiratory track infection.

Global Inhaled Antibiotics Market Cross Sectional Analysis:

North America is expected to dominate the global inhaled antibiotics market over the forecast period, owing to factors such as the product launch is boosting the market and the rising occurrence of asthmatic diseases in the region. For instance, In October 2020, Polyphor, launched an inhaled form of the investigational antibiotic murepavadin (POL7080), which acts specifically against the bacterial strain Pseudomonas aeruginosa, which is a strain found in patients with several lung diseases, including cystic fibrosis- and non-cystic fibrosis-associated bronchiectasis. Thus, the usage of inhaled antibiotics by law enforcement agencies for alcohol and drug abuse is expected to drive the market.

Global Inhaled Antibiotics Market: Key Developments

In November 2022, Lupin Ltd.,, an Indian multinational pharmaceutical company, based in India, announced the launch of Formoterol Fumarate Inhalation Solution, 20 mcg/2 mL per Unit-Dose Vial, to market a generic equivalent of Perforomist Inhalation Solution, 20 mcg/2 mL, of Mylan Specialty, L.P.

In August 2021, Philip Morris International Inc, a U.S.-based Tobacco company, acquired OtiTopic for an undisclosed amount. This acquisition is part of PMI's strategic objective to expand its pipeline of inhaled therapies and respiratory medication delivery by using its expertise, scientific know-how, and inhalation capabilities apart from nicotine. OtiTopic is a U.S.-based respiratory drug development company including inhaled antibotics.

In July 2021, Melinta Therapeutics (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced the commercial launch of KIMYRSA (oritavancin), a lipoglycopeptide antibiotic that delivers a complete course of therapy for acute bacterial skin and skin structure infections (ABSSSI) in a single, one hour, 1,200 mg infusion. The U.S. Food and Drug Administration approved KIMYRSA on March 12, 2021, for the treatment of adult patients with ABSSSI caused by susceptible isolates of designated gram-positive microorganisms.

On June 06, 2023, Spexis AG , a clinical-stage biopharmaceutical company focused on rare diseases and oncology, announced the publication of preclinical results from the company’s novel class of macrocyclic, peptidomimetic antibiotics developed, in collaboration with the University of Zurich, demonstrating potent in vitro and in vivo antimicrobial activity against multidrug resistant (MDR) and extensively drug resistant (XDR) Enterobacteriaceae

Global Inhaled Antibiotics Market: Key Trends

Increasing product approval by regulatory bodies

Increasing product approval by regulatory bodies is expected to offer lucrative growth opportunities for players in the global inhaled antibiotics market. For instance, in April 2020, Raptor Pharmaceutical Corp., a biopharmaceutical company, launched its QUINSAIR (levofloxacin inhalation solution) in Germany and Denmark. It is the first fluoroquinolone to be approved as an inhaled therapy for a pulmonary disease. QUINSAIR is approved in the European Union (EU) and Canada for the management of chronic pulmonary infections caused due to Pseudomonas aeruginosa in adult patients with cystic fibrosis (CF).

Global Inhaled Antibiotics Market: Restraint

Side effects associated with drug inhalation and unattainability of single effective inhaler device

Side effects associated with drug inhalation and unattainability of single effective inhaler device, which is expected to hinder growth of the market. Side-effects related to inhaled antibiotics such as nephrotoxicity, neurotoxicity, dyspnea and many others may hamper the inhaled antibiotics market growth. According to an article published in the National Library of Medicine in October 2021, reported therapy with aerosolized antibiotics often causes local side effects including mild respiratory symptoms, although the occurrence of serious side effects such as bronchospasm, nephrotoxicity, neurotoxicity and dyspnea.

Key market players are focusing on safety and efficacy of drugs.

Global Inhaled Antibiotics Market- Key Players

Major players operating in the global inhaled antibiotics market include Gilead Sciences, Aradigm, Lupin Ltd., Polyphor, Insmed Incorporated, Philip Morris International Inc, Pharmaero, Savara Pharmaceuticals, Joincare Pharmaceutical Group, Teva Pharamceuticals, Altan Pharmaceuticals, Raptor Pharmaceutical Corp. Cipla Limited, Maya Biotech Pvt. Ltd., Medisol Lifescience Pvt. Ltd., Nivon Specialties, Sentiss Pharma Pvt. Ltd., Ultratech India Limited, Midas Care Pharmaceuticals Pvt Ltd., Precept Pharma Ltd., Luckys Pharma, and Pharmaxis Ltd.

*Defination: Inhaled antibiotics refer to drugs that act as medication for respiratory-related problems. Inhaled antibiotics have enhanced survival and have been used to improve lung function, delay deterioration in lung function, extend time between exacerbations, and improve quality of life. The main types of inhaled antibiotics are aerosol or metered dose inhalers, dry powder formulations, sprays and others. A metered-dose inhaler, or MDI, is a device that is frequently used to provide inhaled respiratory drugs. These are used in various applications such as pneumonia, asthma, bronchitis and others, which are used by hospitals, and others.

Table of Content

Table of Contents

*Browse 36 market data tables and 33 figures on “Inhaled Antibiotics Market ”- Global Forecast to 2030

Segmentation

Detailed Segmentation:

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global inhaled antibiotics market during the forecast period (2023-2030)?

The global Inhaled Antibiotics market is estimated to be valued at US$ 1,403.3 Million in 2023 and is expected to exhibit a CAGR of 6.7% between 2023 and 2030.

What are the major factors driving the market growth?

Rising incidence of respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis and growing geriatric population are expected to propel growth to expand the product portfolio is expected to drive the market growth.

Which is the leading Product type segment in the market?

Aerosol is the leading segment in the market.

What are the key factors hampering the growth of the market?

Side effects associated with drug inhalation and unattainability of single effective inhaler device are expected to hinder the market over the forecast period.

Which are the major players operating in the market?

Major players operating in the market include Gilead Sciences, Aradigm, Lupin Ltd., Polyphor, Insmed Incorporated, Pharmaero, Savara Pharmaceuticals, Joincare Pharmaceutical Group, Teva Pharamceuticals, Altan Pharmaceuticals, Raptor Pharmaceutical Corp. Cipla Limited, Maya Biotech Pvt. Ltd., Medisol Lifescience Pvt. Ltd., Nivon Specialties, Sentiss Pharma Pvt. Ltd., Ultratech India Limited, Midas Care Pharmaceuticals Pvt Ltd., Precept Pharma Ltd., Luckys Pharma and Pharmaxis Ltd.